Pharma stocks had a mixed response after Finance Minister Nirmala Sitharaman announced customs duty exemptions for 36 ...

The Nifty Pharma index fell nearly 3% in intraday trade on January 28, marking its third consecutive session of decline, with ...

Alembic's revenue from operations rose to Rs 1,692.74 crore in Q3FY25, a 3.8 per cent Y-o-Y increase from Rs 1,630.57 crore ...

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

The US healthcare system under Trump 2.0 are likely to benefit Indian players, except for the push for increased US drug ...

Most demands for the pharma sector went unattended, failing to trigger any significant upside in pharmaceutical shares.

Indian drugmaker Alembic Pharmaceuticals reported a lower third-quarter profit on Monday, weighed down by weak local sales of its drugs that treat acute illnesses.

Sun Pharmaceutical , India's largest drugmaker by revenue, reported a bigger-than-expected quarterly profit on Friday, aided ...

Indian pharmaceutical companies lag behind global peers in ESG practices, facing regulatory, awareness, and resource ...

India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.

Today, companies including Religare Enterprises, Gland Pharma, Fortis Malar Hospitals, Aditya Birla Capital, Alembic Pharma, ...